Banks E, Reeves G, Beral V, Bull D, Crossley B, Simmonds M, Hilton E, Bailey S, Barrett N, Briers P, English R, Jackson A, Kutt E, Lavelle J, Rockall L, Wallis M G, Wilson M
Cancer Research UK, Epidemiology Unit, Gibson Building, Radcliffe Infirmary, Oxford OX2 6HE, UK.
J Med Screen. 2002;9(2):74-82. doi: 10.1136/jms.9.2.74.
Little is known about the factors influencing the risk of recall for assessment, invasive diagnostic procedures, and early rescreening after screening mammography.
From June 1996 to March 1998 women attending screening at 10 National Health Service Breast Screening Programme (NHSBSP) centres completed a self administered questionnaire and were followed up for their screening outcome.
1969 (3.3%) out of 60 443 women aged 50-64 who had never used hormone replacement therapy (HRT) were recalled for assessment but were not diagnosed with breast cancer (defined here as false positive recall). After adjustment for the variation between centres, false positive recall was decreased significantly among women who were likely to have had a previous NHSBSP mammogram (odds ratio (OR) 0.49, 95% confidence interval (95% CI) 0.38 to 0.63 for likely versus unlikely), who were postmenopausal (OR 0.65, 95% CI 0.56 to 0.76 for postmenopausal v premenopausal) and increased significantly for women reporting previous breast surgery (OR 1.64, 95% CI 1.42 to 1.89). Although false positive recall decreased significantly with parity and increasing body mass index, these effects were not large and no significant variation was found with age, education, family history of breast cancer, oral contraceptive use, sterilisation, exercise, smoking, or alcohol consumption. Altogether 655 (1.1%) women had an invasive diagnostic procedure; no personal characteristics were predictive of this outcome, 286(0.5%) were referred for early rescreening, and this was increased significantly by nulliparity and a family history of breast cancer.
Premenopausal women, those without a previous NHSBSP mammogram, and women with previous breast surgery have an increased risk of false positive recall by the NHSBSP.
关于影响乳腺钼靶筛查后评估召回风险、侵入性诊断程序及早期复查的因素,人们了解甚少。
1996年6月至1998年3月期间,在10个国家医疗服务乳腺筛查项目(NHSBSP)中心接受筛查的女性完成了一份自我管理问卷,并对其筛查结果进行随访。
在60443名年龄在50 - 64岁且从未使用过激素替代疗法(HRT)的女性中,有1969名(3.3%)被召回进行评估,但未被诊断出患有乳腺癌(在此定义为假阳性召回)。在对各中心之间的差异进行调整后,在可能曾接受过NHSBSP乳腺钼靶检查的女性中,假阳性召回显著减少(可能性比值(OR)为0.49,95%置信区间(95%CI)为0.38至0.63,有过检查与未检查相比),绝经后女性也是如此(绝经后与绝经前相比,OR为0.65,95%CI为0.56至0.76),而报告有过乳腺手术史的女性假阳性召回显著增加(OR为1.64,95%CI为1.42至1.89)。尽管假阳性召回随着产次增加和体重指数升高而显著降低,但这些影响不大,且在年龄、教育程度、乳腺癌家族史、口服避孕药使用、绝育、运动、吸烟或饮酒方面未发现显著差异。共有655名(1.1%)女性接受了侵入性诊断程序;没有个人特征可预测这一结果,286名(0.5%)被转诊进行早期复查,并因未生育和乳腺癌家族史而显著增加。
绝经前女性、未曾接受过NHSBSP乳腺钼靶检查的女性以及有过乳腺手术史的女性,NHSBSP假阳性召回风险增加。